Showing results (61-70 of 3,350) with videos related to

Sort By:
Pageof 335
The Lancet. Oncology|March 21, 2018
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trialRui-Hua Xu, Kei Muro, Satoshi Morita, et al.
The Lancet. Oncology|March 26, 2018
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trialReinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
The Lancet. Oncology|October 28, 2017
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trialAlice T Shaw, Enriqueta Felip, Todd M Bauer, et al.
The Lancet. Oncology|January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trialRodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.
The Lancet. Oncology|March 14, 2018
Vulvar field resection based on ontogenetic cancer field theory for surgical treatment of vulvar carcinoma: a single-centre, single-group, prospective trialMichael Höckel, Sophia Trott, Nadja Dornhöfer, et al.
The Lancet. Oncology|March 14, 2018
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trialToni K Choueiri, James Larkin, Mototsugu Oya, et al.
The Lancet. Oncology|February 8, 2018
Cancer surveillance in northern Africa, and central and western Asia: challenges and strategies in support of developing cancer registriesAriana Znaor, Sultan Eser, Hoda Anton-Culver, et al.
The Lancet. Oncology|March 5, 2018
Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trialLin-Quan Tang, Dong-Ping Chen, Ling Guo, et al.
The Lancet. Oncology|February 28, 2018
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trialSabino De Placido, Ciro Gallo, Michelino De Laurentiis, et al.
The Lancet. Oncology|February 14, 2018
Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer GroupHans Wildiers, Konstantinos Tryfonidis, Lissandra Dal Lago, et al.
Pageof 335